TITLE

Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics

AUTHOR(S)
Sorich, M J; Polasek, T M; Wiese, M D
PUB. DATE
September 2013
SOURCE
Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p376
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
From 2010 to 2012, nine systematic reviews reported highly variable conclusions regarding the association between carriage of a cytochrome P450 2C19 loss-of-function allele and the risk of adverse cardiovascular (CV) events in individuals using clopidogrel. Possible contributors to the variable findings include differences in patient populations, CV end points, and statistical models utilized by the systematic reviews, as well as unexplained heterogeneity, inconsistent/incomplete reporting, and risk of publication bias with respect to the primary studies.
ACCESSION #
89806877

 

Related Articles

  • Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Lindh, Jonatan D.; Holm, Lennart; Andersson, Marine L.; Rane, Anders // European Journal of Clinical Pharmacology;Apr2009, Vol. 65 Issue 4, p365 

    To quantify the influence of common cytochrome P450 2C9 ( CYP2C9) polymorphisms on warfarin dose requirements. A systematic review and a meta-analysis, calculating the warfarin dose reduction associated with the five most common variant CYP2C9 genotypes. Thirty-nine studies (7,907 patients) were...

  • Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Mar2011, Vol. 89 Issue 3, p455 

    The article focuses on the association between cytochrome P450 2C19 (CYP2C19) and clopidogrel response in patients under percutaneous coronary interventions. It says that studies from 2008 show that CYP2C19*2 genotype increase the risk of patients to have cardiovascular events but the Platelet...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J-S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317 

    Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious...

  • Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel. Ramirez, Andrea H; Delaney, Jessica T; Shuldiner, Alan R // Evidence Based Medicine;Aug2011, Vol. 16 Issue 4, p124 

    The article presents a commentary on the study "Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis," published in a 2010 issue of the "Journal of American Medical Association." It notes the...

  • Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Fleeman, N; Dundar, Y; Dickson, R; Jorgensen, A; Pushpakom, S; McLeod, C; Pirmohamed, M; Walley, T // Pharmacogenomics Journal;Feb2011, Vol. 11 Issue 1, p1 

    There is wide variability in the response of individuals to standard doses of antipsychotic drugs. It has been suggested that this may be partly explained by differences in the cytochrome P450 (CYP450) enzyme system responsible for metabolizing the drugs. We conducted a systematic review and...

  • A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Blake, C M; Kharasch, E D; Schwab, M; Nagele, P // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p394 

    Metoprolol, a commonly prescribed β-blocker, is primarily metabolized by cytochrome P450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Several smaller studies have shown that metoprolol pharmacokinetics is influenced by CYP2D6 genotype and metabolizer phenotype. To increase...

  • Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Takahashi, M; Saito, T; Ito, M; Tsukada, C; Katono, Y; Hosono, H; Maekawa, M; Shimada, M; Mano, N; Oda, A; Hirasawa, N; Hiratsuka, M // Pharmacogenomics Journal;Feb2015, Vol. 15 Issue 1, p26 

    Genetic variations in cytochrome P450 2C19 (CYP2C19) contribute to interindividual variability in the metabolism of therapeutic agents such as clopidogrel. Polymorphisms in CYP2C19 are associated with large interindividual variations in the therapeutic efficacy of clopidogrel. This study...

  • Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Martis, S; Peter, I; Hulot, J-S; Kornreich, R; Desnick, R J; Scott, S A // Pharmacogenomics Journal;Aug2013, Vol. 13 Issue 4, p369 

    To determine CYP2C19 and CYP2C8 allele frequencies, 28 coding and/or functional variants were genotyped in 1250 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) individuals. The combined CYP2C19 variant allele frequencies ranged from ∼0.30 to 0.41; however, the CYP2C8...

  • Effect of CYP2C19 variants on clopidogrel.  // Internal Medicine Alert;11/17/2009 Supplement, p21 

    The article reports on the results of a study which investigates the effect of CYP2C19 or P450 2C19 metabolite variants on clopidogrel.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics